Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Increases By 24.7%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 1,945,809 shares, a growth of 24.7% from the January 15th total of 1,559,953 shares. Approximately 5.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 488,835 shares, the days-to-cover ratio is presently 4.0 days. Based on an average daily trading volume, of 488,835 shares, the days-to-cover ratio is presently 4.0 days. Approximately 5.5% of the shares of the stock are sold short.

Institutional Trading of SAB Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC acquired a new position in SAB Biotherapeutics in the 3rd quarter worth approximately $30,000. Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics in the third quarter valued at $32,000. State of Wyoming acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter worth $34,000. Virtu Financial LLC purchased a new position in shares of SAB Biotherapeutics during the third quarter valued at $40,000. Finally, State Street Corp acquired a new position in SAB Biotherapeutics during the fourth quarter valued at $49,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Trading Down 6.6%

Shares of SABS traded down $0.27 on Monday, hitting $3.85. 274,534 shares of the stock traded hands, compared to its average volume of 373,239. SAB Biotherapeutics has a 1 year low of $1.00 and a 1 year high of $6.60. The stock’s 50 day moving average is $3.96 and its two-hundred day moving average is $3.13. The company has a quick ratio of 10.50, a current ratio of 10.49 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $183.30 million, a P/E ratio of -1.25 and a beta of 0.58.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.38. As a group, sell-side analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday, December 29th. UBS Group began coverage on shares of SAB Biotherapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of SAB Biotherapeutics in a research note on Thursday, December 18th. Finally, Guggenheim began coverage on shares of SAB Biotherapeutics in a report on Friday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.